Weiner H - Search Results

1

Therapeutic considerations for disease progression in multiple sclerosis: evidence, experience, and future expectations.

Frohman EM, Stüve O, Havrdova E, Corboy J, Achiron A, Zivadinov R, Sorensen PS, Phillips JT, Weinshenker B, Hawker K, Hartung HP, Steinman L, Zamvil S, Cree BA, Hauser S, Weiner H, Racke MK, Filippi M. Frohman EM, et al. Among authors: weiner h. Arch Neurol. 2005 Oct;62(10):1519-30. doi: 10.1001/archneur.62.10.1519. Arch Neurol. 2005. PMID: 16216934 Review.

2

Cutting edge: oral type I IFN-tau promotes a Th2 bias and enhances suppression of autoimmune encephalomyelitis by oral glatiramer acetate.

Soos JM, Stüve O, Youssef S, Bravo M, Johnson HM, Weiner HL, Zamvil SS. Soos JM, et al. J Immunol. 2002 Sep 1;169(5):2231-5. doi: 10.4049/jimmunol.169.5.2231. J Immunol. 2002. PMID: 12193686

3

Multiple sclerosis is an inflammatory T-cell-mediated autoimmune disease.

Weiner HL. Weiner HL. Arch Neurol. 2004 Oct;61(10):1613-5. doi: 10.1001/archneur.61.10.1613. Arch Neurol. 2004. PMID: 15477521 Review. No abstract available.

4

Most patients with multiple sclerosis or a clinically isolated demyelinating syndrome should be treated at the time of diagnosis.

Frohman EM, Havrdova E, Lublin F, Barkhof F, Achiron A, Sharief MK, Stuve O, Racke MK, Steinman L, Weiner H, Olek M, Zivadinov R, Corboy J, Raine C, Cutter G, Richert J, Filippi M. Frohman EM, et al. Among authors: weiner h. Arch Neurol. 2006 Apr;63(4):614-9. doi: 10.1001/archneur.63.4.614. Arch Neurol. 2006. PMID: 16606781 No abstract available.

5

Natalizumab: immune effects and implications for therapy.

Hauser SL, Weiner HL. Hauser SL, et al. Ann Neurol. 2006 May;59(5):731-2. doi: 10.1002/ana.20877. Ann Neurol. 2006. PMID: 16634007 No abstract available.

6

Natalizumab treatment for multiple sclerosis: recommendations for patient selection and monitoring.

Kappos L, Bates D, Hartung HP, Havrdova E, Miller D, Polman CH, Ravnborg M, Hauser SL, Rudick RA, Weiner HL, O'Connor PW, King J, Radue EW, Yousry T, Major EO, Clifford DB. Kappos L, et al. Among authors: weiner hl. Lancet Neurol. 2007 May;6(5):431-41. doi: 10.1016/S1474-4422(07)70078-9. Lancet Neurol. 2007. PMID: 17434098 Review.

7

Intense immunosuppression in patients with rapidly worsening multiple sclerosis: treatment guidelines for the clinician.

Boster A, Edan G, Frohman E, Javed A, Stuve O, Tselis A, Weiner H, Weinstock-Guttman B, Khan O; Multiple Sclerosis Clinical Research Center, Department of Neurology, Wayne State University School of Medicine. Boster A, et al. Among authors: weiner h. Lancet Neurol. 2008 Feb;7(2):173-83. doi: 10.1016/S1474-4422(08)70020-6. Lancet Neurol. 2008. PMID: 18207115 Review.

8

A shift from adaptive to innate immunity: a potential mechanism of disease progression in multiple sclerosis.

Weiner HL. Weiner HL. J Neurol. 2008 Mar;255 Suppl 1:3-11. doi: 10.1007/s00415-008-1002-8. J Neurol. 2008. PMID: 18317671 Review.

9

Predicting clinical progression in multiple sclerosis with the magnetic resonance disease severity scale.

Bakshi R, Neema M, Healy BC, Liptak Z, Betensky RA, Buckle GJ, Gauthier SA, Stankiewicz J, Meier D, Egorova S, Arora A, Guss ZD, Glanz B, Khoury SJ, Guttmann CR, Weiner HL. Bakshi R, et al. Arch Neurol. 2008 Nov;65(11):1449-53. doi: 10.1001/archneur.65.11.1449. Arch Neurol. 2008. PMID: 19001162 Free PMC article.

10

Rate of brain atrophy in benign vs early multiple sclerosis.

Gauthier SA, Berger AM, Liptak Z, Duan Y, Egorova S, Buckle GJ, Glanz BI, Khoury SJ, Bakshi R, Weiner HL, Guttmann CR. Gauthier SA, et al. Arch Neurol. 2009 Feb;66(2):234-7. doi: 10.1001/archneurol.2008.567. Arch Neurol. 2009. PMID: 19204160

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

1,360 results

Search Page

Filters